Insilico Medicine Snaps Up $60M to Create Robotic Lab of the Future

by Andrii Buvailo, PhD          News

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

   2438    Comments 0
Topics: Emerging Technologies   
Share:   Share in LinkedIn  Share in Reddit  Share in X  Share in Hacker News  Share in Facebook  Send by email

Hong Kong-based pioneer of the artificial intelligence (AI)-driven drug discovery, a clinical stage biotech Insilico Medicine, has completed a $60 million Series D financing from a syndicate of newly joined high-profile investors, including diversified asset management firm on the US West Coast and BHR Partners, along with current investors, including Warburg Pincus, B Capital Group, Qiming Venture Partners, BOLD Capital Partners and Pavilion Capital. Notably, the company’s founder and CEO, Dr. Alex Zhavoronkov, also invested in the Series D round.

Part of the newly raised money will be spent on advancing its lead program in fibrosis which is currently in a Phase I study, and further expanding its proprietary end-to-end AI-driven platform Pharma.AI, comprising of three key modules: PandaOmics™ for target discovery; Chemistry42™ for generative drug design; and InClinico™ for predicting clinical trial outcomes. It should be noted that Pharma.AI platform already demonstrated a repeated ability to reach drug discovery milestones rapidly. Since the previous round seven programs in its internal pipeline have progressed to the IND-enabling stage, including a novel 3CL protease inhibitor for COVID-19 treatment, and two synthetic lethality programs targeting MAT2A and USP1 for oncology. It also successfully completed a Phase 0 microdose study and entered a Phase I clinical trial with its first internally developed program targeting fibrosis. In this respect, the new and existing investors have a demonstrated proof-of-concept and feasibility, which is reflected in the company’s ability to win their trust with yet another round, during the times of unprecedentedly tough market conditions, bringing the total raised capital on the balance of Insilico Medicine to a whopping $366 million.

Another strategic direction the company is planning to pursue with the additional funding is building a fully automated, AI-driven robotic drug discovery laboratory, and fully robotic biological data factory to complement Insilico’s existing data assets. 

Continue reading

This content available exclusively for BPT Mebmers

Topics: Emerging Technologies   

Share:   Share in LinkedIn  Share in Reddit  Share in X  Share in Hacker News  Share in Facebook  Send by email

Comments:

There are no comments yet. You can be the first.

Leave a Reply

Your email address will not be published. Required fields are marked *